Q-omics provides the consensus-scored EXOC7 profile across patient tissues and cancer cell-line models. EXOC7 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, EXOC7 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, EXOC7 protein abundance shows 22,033 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight BRCA, KIRC, and PDAC as cancer lineages where EXOC7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EXOC7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EXOC7 survival associations across molecular data types. EXOC7 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (10) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EXOC7 RNA expression–survival associations across cancer types. High EXOC7 expression shows unfavorable associations in ACC, KICH and LIHC, but favorable associations in BRCA, KIRC and LUAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for EXOC7 RNA expression.
This table summarizes EXOC7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for EXOC7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EXOC7 shows lower tumor expression in KICH and BRCA and higher tumor expression in KIRC, KIRP, LIHC and CHOL. The KIRC box plot shows higher EXOC7 RNA expression in tumor versus normal tissue (log2 FC = +0.695, t-test p < 0.001).
This table shows molecular features associated with EXOC7 in patient tissues and cancer cell lines. In patient samples, EXOC7 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, EXOC7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
